263 related articles for article (PubMed ID: 29723302)
1. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
Gong Y; Yang J; Wu W; Liu F; Su A; Li Z; Zhu J; Wei T
PLoS One; 2018; 13(5):e0197007. PubMed ID: 29723302
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer.
Gu Y; Hu C
Biofactors; 2019 Nov; 45(6):902-911. PubMed ID: 31498939
[TBL] [Abstract][Full Text] [Related]
3. The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.
Gu Y; Feng C; Liu T; Zhang B; Yang L
PLoS One; 2018; 13(12):e0209338. PubMed ID: 30576338
[TBL] [Abstract][Full Text] [Related]
4.
Luo J; Zhang B; Cui L; Liu T; Gu Y
Future Oncol; 2019 Apr; 15(12):1303-1311. PubMed ID: 30757917
[No Abstract] [Full Text] [Related]
5. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
6. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
7. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
10. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
12. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
13. RAP1GAP Functions as a Tumor Suppressor Gene and Is Regulated by DNA Methylation in Differentiated Thyroid Cancer.
Faam B; Ghaffari MA; Khorsandi L; Ghadiri AA; Totonchi M; Amouzegar A; Fanaei SA; Azizi F; Shahbazian HB; Hashemi Tabar M
Cytogenet Genome Res; 2021; 161(5):227-235. PubMed ID: 34311462
[TBL] [Abstract][Full Text] [Related]
14. Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer.
Ma B; Liao T; Wen D; Dong C; Zhou L; Yang S; Wang Y; Ji Q
Sci Rep; 2016 Nov; 6():36973. PubMed ID: 27833134
[TBL] [Abstract][Full Text] [Related]
15. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer.
Li Q; Li H; Zhang L; Zhang C; Yan W; Wang C
Oncotarget; 2017 Jul; 8(28):46136-46144. PubMed ID: 28545026
[TBL] [Abstract][Full Text] [Related]
17. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
18. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
19. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract][Full Text] [Related]
20. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
